Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E17.01 EPS (ttm)10.26 Insider Own0.10% Shs Outstand734.13M Perf Week1.42%
Market Cap128.15B Forward P/E13.61 EPS next Y12.83 Insider Trans0.00% Shs Float733.56M Perf Month14.06%
Income7.72B PEG2.51 EPS next Q2.99 Inst Own80.20% Short Float0.81% Perf Quarter21.78%
Sales22.99B P/S5.57 EPS this Y13.10% Inst Trans-2.09% Short Ratio1.66 Perf Half Y3.58%
Book/sh40.59 P/B4.30 EPS next Y3.95% ROA10.10% Target Price184.58 Perf Year22.08%
Cash/sh51.88 P/C3.36 EPS next 5Y6.79% ROE25.90% 52W Range131.83 - 174.70 Perf YTD20.21%
Dividend4.60 P/FCF19.66 EPS past 5Y20.50% ROI13.00% 52W High-0.08% Beta1.22
Dividend %2.64% Quick Ratio3.90 Sales past 5Y8.10% Gross Margin81.90% 52W Low32.41% ATR2.76
Employees19200 Current Ratio4.10 Sales Q/Q7.70% Oper. Margin42.60% RSI (14)78.88 Volatility1.55% 1.68%
OptionableYes Debt/Eq1.16 EPS Q/Q10.50% Profit Margin33.60% Rel Volume0.75 Prev Close174.01
ShortableYes LT Debt/Eq1.01 EarningsFeb 02 AMC Payout38.70% Avg Volume3.55M Price174.56
Recom2.30 SMA205.66% SMA5011.65% SMA20011.35% Volume2,666,700 Change0.32%
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Feb-26-17 11:20AM  3 Stocks You Don't Have to Babysit at Motley Fool
Feb-23-17 05:06PM  AbbVie Stronger Bet Than Gilead, Amgen At Least Until 2020: Leerink
01:45PM  In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs at bizjournals.com
09:31AM  Amgen Signs Value-Based Deal for Enbrel at Investopedia
08:00AM  Big Pharma Quietly Enlists Leading Professors to Justify $1,000-a-Day Drugs
Feb-22-17 06:21PM  Who Could Buy Bristol-Myers Squibb? at Motley Fool
01:30PM  Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease at Motley Fool
12:21PM  Genmab and J&J's cancer drug set for blockbuster sales this year
10:37AM  Keytruda: Mercks Immuno-Oncology Blockbuster Drug
10:30AM  Amgen Gets EU Nod for Monthly Repatha Dose at Investopedia
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb-21-17 04:48PM  Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
04:00PM  Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option PR Newswire
09:34AM  Top Research Reports for Amgen, Bank of America, and Proctor & Gamble
08:54AM  Study Reveals PCSK9 Drugs Can Save Heart Disease Patients at Motley Fool
07:36AM  How Amgens Kyprolis Is Positioned in Second-Line Multiple Myeloma Segment
Feb-20-17 12:15PM  Roche Sues Amgen Over Avastin Biosimilar Drug at Investopedia
10:36AM  Repatha Represents a Solid Growth Opportunity for Amgen in 2017
09:06AM  Amgens Neutropenia Drugs May See Falling Revenues in 2017
07:36AM  Enbrel Strengthens Its Position in Rheumatology and Dermatology Segments
Feb-18-17 01:04PM  AMGEN INC Financials
Feb-17-17 03:34PM  Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
10:36AM  Amgen Is Managing the Life Cycle of Its Mature Nephrology Drugs in 2017
09:12AM  Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
09:07AM  Parsabiv Is Expected to Boost Amgens Revenues in 2017
07:37AM  Prolia Expected to Be a Significant Growth Driver for Amgen in 2017
Feb-16-17 05:35PM  Amgen Commits to Reaching Its Long-Term Financial Targets in 2018
04:41PM  Don't Count on Valeant's New Drug to Save the Day at Motley Fool
03:36PM  Amgen Estimates Modest Revenue Performance in 2017
11:18AM  Health Care ETF Has Been Ailing
09:20AM  Why Amgen's Becoming One of My Top Dividend Stocks to Buy at Motley Fool
Feb-15-17 06:35PM  Cramer fires back at naysayers: Here's your proof that th...
05:59PM  Proof the rally is real
05:19PM  Biotech boom?
12:22PM  Amgen Applies for Leukemia Drug Label Expansion at Investopedia
09:48AM  Want to Get In on Biotech? Check Out These 3 Stocks at Motley Fool
08:31AM  Amgen Looking to Broaden Leukemia Drug Blincyto's Label
Feb-14-17 05:07PM  AMGEN INC Files SEC form 10-K, Annual Report
09:00AM  Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia PR Newswire
Feb-13-17 05:30PM  Daniel Loeb Picks Up Rate-Sensitive Financials, Drops Pharma
Feb-10-17 09:55AM  Major Biotechs Scare Off Loads of Short Sellers
08:38AM  Biotech ETFs Powered by Q4 Earnings
Feb-09-17 04:56PM  Regeneron Defies Light Q4 Sales, Eylea Outlook On Amgen-Rivaling LDL Win
02:01PM  Regeneron: Whiplash! at Barrons.com
01:11PM  Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales at Insider Monkey
11:09AM  Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
10:56AM  Judge Lifts Ban on Amgen Cholesterol Drug Rival at Investopedia
09:05AM  Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
08:31AM  Regeneron forecasts 2017 U.S. Eylea sales growth below estimates
08:17AM  A Heart-Stopping Patent Injunction Stay For Sanofi at Forbes
Feb-08-17 07:02PM  [$$] Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug at The Wall Street Journal
05:45PM  Gilead tanks on weak forecast
05:33PM  Regeneron, Sanofi Temporarily Stave Off Ban Of Amgen-Rivaling LDL-Buster
04:49PM  Federal appeals court decision will keep Regeneron/Sanofi drug at center of patent dispute on market, for now at MarketWatch
04:39PM  Judge: Regeneron can keep selling cholesterol drug
04:14PM  Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
12:48PM  FDA Approves Amgen, Inc. (AMGN) Drug For Treating Secondary Hyperparathyroidism at Insider Monkey
12:03PM  Why Coherus Biosciences Is Falling Today at Motley Fool
11:39AM  Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback at Insider Monkey
10:48AM  Amgen Gets FDA Approval for Kidney Drug Parsabiv at Investopedia
09:02AM  Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.
08:23AM  Better Buy: Amgen Inc. vs. Celgene at Motley Fool
06:45AM  Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib
03:25AM  Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A
Feb-07-17 07:05PM  Cramer: The right time to buy more oil stocks at CNBC
06:20PM  U.S. FDA approves Amgen drug for secondary hyperparathyroidism Reuters
06:13PM  FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis PR Newswire
02:08PM  Amgen, Inc. :AMGN-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017
12:50PM  Whats Next For Esperion Therapeutics Inc (ESPR)? at Insider Monkey
09:06AM  Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More
Feb-06-17 12:40PM  Priced like an automaker, sputtering Gilead shares lure value bets
10:44AM  Amgen, Inc. :AMGN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017
10:10AM  Company News for February 06, 2017
08:02AM  Amgen Stock Buoyed By Positive Repatha Study at Investopedia
12:42AM  [$$] Good News for Amgen Is Good News for Biotech at The Wall Street Journal
Feb-05-17 07:23AM  Trump's Plan to Lower Drug Costs Is a Fairy Tale at Motley Fool
Feb-03-17 06:11PM  Trading Friday's rally: 6 plays at CNBC
05:49PM  Why Morgan Stanley, Amgen, and Tableau Software Jumped Today at Motley Fool
05:05PM  Banks lead stock surge as investors hope for regulation cuts
04:32PM  Why The Medicines Company Rocketed Higher Today at Motley Fool
04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
04:15PM  BetterInvesting Magazine Releases April Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use PR Newswire
04:04PM  Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors PR Newswire
03:38PM  Why Esperion Therapeutics, Inc. Is Soaring Today at Motley Fool
03:15PM  Amgen: Who Says Biotech's Dead? at Barrons.com
12:43PM  [$$] Good News for Amgen Is Good News for Biotech at The Wall Street Journal
12:16PM  Repatha Will Test the New Drug Pricing Reality at Bloomberg
11:08AM  Amgen Q4 Earnings Beat Street Forecasts at Investopedia
10:47AM  Dow Retakes 20,000 As Visa, Goldman, Rally; Amazon Sinks, But Amgen Soars
10:25AM  Stocks Open Higher As Payrolls Surge, Dow Passes 20,000 Again
08:38AM  Are Options Traders Betting on a Big Move in Amgen (AMGN) Stock?
08:01AM  Early movers: AMZN, CLX, AN, HSY, F, AMGN & more at CNBC
06:59AM  Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study
04:40AM  Edited Transcript of AMGN earnings conference call or presentation 2-Feb-17 10:00pm GMT
Feb-02-17 07:20PM  Fast Money traders discuss how to trade Amgen and Amazon earnings at CNBC
06:50PM  [$$] Amgen Sees Positive Results in Repatha Study at The Wall Street Journal
06:15PM  Amgen fourth quarter profit tops Street view, cholesterol news lifts shares
06:14PM  Amgen 4th-qtr profit tops Street view, cholesterol news lifts shares
05:49PM  Amgen CEO: Will work with Trump to lower drug prices
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM